NCT01576666 2020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
Novartis
Novartis
Novartis
SCRI Development Innovations, LLC
Dana-Farber Cancer Institute
Novartis